At a Glance
| Feature | Detail |
|---|---|
| Class | Designer analog of Semax (ACTH-derived heptapeptide) with N-terminal acetylation and a C-terminal adamantane-containing amide cap |
| Origin | Nootropics market, mid-2020s; no academic developer or patent publication identified |
| Proposed mechanism | Assumed to act like Semax (BDNF/TrkB upregulation, dopaminergic and serotonergic modulation); never tested |
| Used for | Focus, mental energy, study and work performance |
| Route | Intranasal (most common), subcutaneous |
| Typical dose range | 200–500 mcg intranasal or 200–300 mcg subcutaneous, once daily, 2–4 week cycles |
| Evidence level | Limited: no published study on Adamax itself; all evidence is borrowed from Semax and P021 |
| Regulatory status | Not approved anywhere; not on FDA’s 503A lists; no EU/German authorisation; proposed for prescription scheduling in New Zealand; WADA S0 (non-approved substance) |
Adamax is what happens when the nootropics market takes two research ideas and merges them without a lab in between. The core is Semax, the ACTH-derived peptide that has been a registered medicine in Russia since the 1990s. The ends come from P021, a CNTF-derived research peptide from the Iqbal lab in New York, which carries an acetyl group at the front and an adamantane-containing residue at the back to resist breakdown.
The logic is easy to follow. Semax is short-lived; the adamantane cap made P021 active after oral dosing in mice; so a capped Semax should last longer and hit harder. That is a hypothesis. Nobody has published a single measurement of Adamax: no binding data, no half-life, no animal study, no human pharmacokinetics.
My verdict up front: Adamax is a self-experiment with an unknown molecule. If the goal is the Semax effect, the parent compound has decades of clinical use behind it and this one has none.
What Adamax Actually Is
The most consistent description, shared by Wikipedia and the New Zealand regulator’s 2025 classification paper, is a designer analogue of Semax carrying the N-terminal and C-terminal modifications found in Peptide 021 [1]. Wikipedia gives the backbone as Ac-MEHFPGPAG-NH2 with an adamantane group attached near the C-terminus. Vendor pages disagree on how the adamantane is attached and even on how many residues the molecule has, which tells you something about the product category: there is no reference standard.
The parent molecules are better characterised:
- Semax (Met-Glu-His-Phe-Pro-Gly-Pro) raised hippocampal BDNF and TrkB expression in rats after a single dose [2], and activated dopaminergic and serotonergic systems in rodents [3]. See the full Semax article.
- P021 (Ac-DGGL^AG-NH2) was designed so the adamantane-containing residue would protect the peptide from peptidases and improve brain entry. In the first paper describing the series, peripheral dosing improved learning and memory and increased neurogenesis in normal mice [4]. See the P021 article.
Neither finding transfers automatically. Adding a bulky lipophilic group to a peptide can change receptor binding, tissue distribution and immunogenicity in either direction.
How It Is Supposed to Work
The intended mechanism is the Semax mechanism with a longer clock. Semax acts centrally without the cortisol-releasing activity of full ACTH. Its best-documented effect in animals is a rise in BDNF and its receptor TrkB in the hippocampus [2], plus increased dopamine and serotonin turnover [3]. The adamantane cap is meant to slow enzymatic cleavage, so the same dose would act for longer.
Users’ descriptions fit a stronger dopaminergic push: most call it more stimulating than Semax. Whether that reflects a longer half-life, a different receptor profile, a higher real content in the vial, or expectation is unknown.
What the Evidence Shows
Human trials on Adamax: none. A PubMed search for “Adamax” returns only machine-learning papers that use an optimiser of the same name.
Animal or cell studies on Adamax: none published.
Borrowed evidence:
- Semax: rodent BDNF/TrkB data [2], rodent neurotransmitter data [3], and Russian clinical use in stroke. Western regulators have not authorised it, and FDA lists Semax among substances whose compounding nominations were withdrawn, with a note on immunogenicity risk and missing human safety data [5].
- P021: neurogenesis and memory effects in normal mice [4], aged rats [6] and Alzheimer-model mice [7]. No human studies.
Regulatory documentation: Medsafe’s June 2025 submission to New Zealand’s Medicines Classification Committee proposed a group entry covering any analogues of ACTH, naming Adamax and Semax as two peptide products currently marketed as cognitive enhancers [1]. Wikipedia also notes Adamax has turned up as a designer drug in border seizures.
That is the full evidence base.
Dosing
For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.
No trial has tested any dose of Adamax. The numbers below come from published protocol sites and community reports, labelled by basis.
| Goal | Dose | Route | Frequency / timing | Cycle length | Basis |
|---|---|---|---|---|---|
| First exposure / tolerance check | 100–200 mcg | Subcutaneous or intranasal | Once, morning | 2–3 days, then reassess | Anecdotal (peptide-db, community reports) |
| Focus and mental energy (standard) | 200–300 mcg | Subcutaneous | Once daily, morning | 2–4 weeks on, then equal time off | Practice protocol (peptide-db; Peptide Dosing Protocols, weeks 1–2) |
| Focus (intranasal) | 200–500 mcg | Intranasal | Once daily, morning; some split into morning and midday | 2–4 weeks | Anecdotal (Peptide Dosing Protocols; r/Biohackers and r/peptidesAustralia reports) |
| “Neuroprotection” framing | 300 mcg | Subcutaneous | 1–2× daily | 2–4 weeks | Anecdotal (peptide-db) |
| Titration schedule | 300 → 500 → 750 → 1,000 mcg, stepping up every 2 weeks | Subcutaneous | Once daily | 8 weeks | Anecdotal (single published schedule, Peptide Dosing Protocols) |
| Stack: focus plus calm | Adamax 200–500 mcg + Selank 250–500 mcg | Intranasal | Morning | 1–3 weeks | Anecdotal (r/Biohackers) |
Practical points that come up repeatedly:
- Timing. Morning only. Afternoon doses are the most common source of the sleep complaints.
- Titration. Start at the bottom of the range for 2–3 days. People switching from NA-Semax tend to start at half their usual Semax dose because of the stronger stimulation others describe.
- Off-cycle. The usual pattern copies Semax cycling: 2–4 weeks on, at least the same time off. Nothing is known about tolerance to Adamax specifically.
- Intranasal preparation. A 5 mg vial reconstituted with 2.5 mL bacteriostatic water gives 2 mg/mL; a nasal pump that delivers 0.1 mL per actuation then gives about 200 mcg per spray. Blow the nose first, tilt the head slightly forward, spray while breathing in gently, and do not sniff hard afterwards. Pump volumes differ between devices, so check yours.
- Subcutaneous technique and reconstitution: see the peptide injection guide.
What People Report: What Works and What Doesn’t
Community reports on Adamax are few, recent, and often from people who also use Semax, Selank or stimulants. Treat this as a map of what people describe, not as evidence.
Reported to work
- Acute focus and mental clarity within minutes to a few hours of 200–500 mcg intranasally, lasting roughly three to four hours (r/peptidesAustralia, r/Biohackers).
- A one-month self-report at about 150 mcg subcutaneously described it as a much more stimulating Semax, with a subjective sense of sharper thinking and little difference between injected and nasal use (r/NooTopics review).
Mixed or unclear
- Whether it beats Semax: one experienced user called it not much better than NA-Semax and not worth the price (r/NooTopics).
- Route: one user felt nothing from 300 and 600 mcg subcutaneously except hours of head pressure and planned to switch to nasal use (a single user report; the thread sits in a vendor-affiliated subreddit, so it is not linked here).
Reported not to work, or disappointing
- Complete non-response, with users calling it their most regretted nootropic purchase and questioning what the vial contained (r/Nootropics).
- Side effects people describe: an anxious comedown after the stimulation fades, head pressure, headache, and poor sleep with later doses.
What a proper trial would need to show: that the molecule in the vial is what the label says, its half-life in humans, and a blinded comparison against Semax and placebo on a predefined cognitive endpoint.
Safety and Side Effects
No safety study exists for Adamax. What can be said:
- Expected effects, by analogy with Semax: nasal irritation, restlessness, overstimulation, sleep disruption, appetite change. Users report all of these.
- Unknowns specific to the modification: an adamantane group changes lipophilicity and could change brain exposure, duration and immunogenicity. FDA’s stated concern about Semax compounding was immunogenicity [5]; there is no reason to assume a novel analog carries less risk.
- Who should not experiment: people with seizure disorders, bipolar disorder or a history of mania, anxiety disorders that worsen with stimulants, pregnancy and breastfeeding, and anyone on MAO inhibitors or stimulant medication.
- Product risk: every vial is a grey-market product with no reference standard. Identity, content, sterility and endotoxin are unknown unless independently tested, and even a certificate of analysis cannot confirm a structure that has never been published.
Legal and Regulatory Status
- US: Not FDA-approved. Adamax does not appear on FDA’s 503A bulk-substance lists, so compounding pharmacies have no route to use it. It is sold as a “research chemical” not for human use. Its parent, Semax, sits on FDA’s list of withdrawn nominations with a safety-risk note [5].
- EU / Germany: No marketing authorisation. A product sold for human use to influence brain function meets the functional definition of a medicinal product, so selling it for that purpose without authorisation is not legal.
- New Zealand: Medsafe has proposed scheduling ACTH analogs including Adamax and Semax as prescription medicines [1]; its 2026 consumer advisory states that importing, selling or using unapproved peptide products is illegal.
- Sport: Not approved by any health authority, so it falls under WADA’s S0 (non-approved substances), prohibited at all times.
How Adamax Fits Among the Cognitive Peptides
| Semax | Adamax | P021 | |
|---|---|---|---|
| Human data | Russian clinical use and trials | None | None |
| Animal data | Yes (BDNF, neurotransmitters) | None | Yes (neurogenesis, memory, Alzheimer models) |
| Approved anywhere | Russia | No | No |
| Typical use | 300–600 mcg/day intranasal | 200–500 mcg/day intranasal | 500 mcg–1 mg/day subcutaneous (community) |
| Main open question | Western-standard RCTs | What the molecule is and does | Whether mouse data translate |
If someone is set on an ACTH-analog effect, standard Semax is the compound with the longest record. Adamax adds an unknown on top of a known.
Related Articles
- Semax: The Nootropic Peptide That Amplifies BDNF and Protects the Brain
- Selank vs Semax: Which Nootropic Peptide Is Right for You?
- Nootropic Peptides: A Physician’s Guide to Cognitive Enhancement
- P021: The CNTF-Derived Peptide With Only Mouse Data
- FDA 2026 Peptide Compounding Update: What the Category Lists Say
- How to Inject Peptides: A Step-by-Step Patient Guide
Frequently asked questions
What is Adamax peptide?
Adamax is a synthetic analog of Semax, the ACTH-derived heptapeptide. It adds an N-terminal acetyl group and a C-terminal adamantane-containing cap, the same end modifications used in the research peptide P021. It appeared in the nootropics market in the mid-2020s and has no published pharmacology or human data.
Is Adamax stronger than Semax?
Users often describe it as more stimulating than Semax or NA-Semax, but no study has compared them. Some users report no effect at all. Claims of longer duration come from the chemistry rationale, not from measured pharmacokinetics.
What dose of Adamax do people use?
Circulating protocols use 200 to 500 mcg intranasally in the morning, or 200 to 300 mcg subcutaneously once daily, for 2 to 4 weeks. One published schedule titrates from 300 mcg to 1,000 mcg daily over 8 weeks. None of these doses has been tested in a trial.
Is Adamax legal?
Adamax has no marketing authorisation in any country. In the EU and US it is sold as a 'research chemical', which does not make human use legal or safe. New Zealand's Medsafe has proposed classifying ACTH analogs such as Adamax and Semax as prescription medicines. For athletes it falls under WADA's S0 class of non-approved substances.
What are the side effects of Adamax?
No safety study exists. Users most often describe overstimulation, a mild anxious comedown, head pressure, headache and disturbed sleep when taken late in the day. Purity and identity of grey-market vials are unknown.
References
- Medsafe (New Zealand Medicines and Medical Devices Safety Authority). Classification of Unscheduled Peptides. Submission to the Medicines Classification Committee, meeting 74. June 2025. https://medsafe.govt.nz/Profs/class/Agendas/Agen74/5.7Peptides.pdf
- Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54-60. https://pubmed.ncbi.nlm.nih.gov/16996037/
- Eremin KO, Kudrin VS, Saransaari P, et al. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005;30(12):1493-1500. https://pubmed.ncbi.nlm.nih.gov/16362768/
- Li B, Wanka L, Blanchard J, et al. Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptic plasticity in mice. FEBS Lett. 2010;584(15):3359-3365. https://pubmed.ncbi.nlm.nih.gov/20600002/
- U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (table of nominated-but-withdrawn substances: Semax). Accessed October 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- Bolognin S, Buffelli M, Puoliväli J, Iqbal K. Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound. Neurobiol Aging. 2014;35(9):2134-2146. https://pubmed.ncbi.nlm.nih.gov/24702821/
- Kazim SF, Blanchard J, Dai CL, et al. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer’s disease. Neurobiol Dis. 2014;71:110-130. https://pubmed.ncbi.nlm.nih.gov/25046994/
